The Holy Pyramid [Of Profits]

CRISPR is sure to make biotech history. But its life-changing profit potential lies in the hands of a pyramid patent battle.

There is $30 trillion in global potential up for grabs now that CRISPR has hit the market.

But there is a fierce debate over CRISPR intellectual property rights. The CRISPR field is really hot, and I expect there will be Nobel Prizes forthcoming at some point for the discoverers — depending on who gets the credit.

It would be a very big deal who gets the credit for owning the CRISPR technology. But it’s currently in a tough legal battle over who will reign supreme.

Luckily, the patent battle hasn’t stopped biotech researchers from working to commercialize CRISPR for human therapies.

Three companies, three different approaches, three brilliant minds, and three ways to potentially profit from this one revolutionary discovery.

All three scientists at the helm are fighting for the rights to CRISPR and its incredible potential to transform the landscape of how we treat disease.

You have the fortunate advantage of not needing to pick a side. Because no matter who wins this battle the real opportunity lies in the technology itself.

My three point strategy will put you in the most profitable position you can be in.

Where It All Began

The beginning of this phenomenon started with a biological accident. An accident that created what is now being called the “the biggest biotech discovery of the century”.

What started as curiosity quickly became a moment of revelation. Doctors Jennifer Doudna and Emmanuelle Charpentier were studying the system in which bacteria defends themselves against viruses.

What came of that research is now history.

The process bacteria uses to shut down viruses targets a specific section of DNA and cuts up the viral genes floating around.

Mimicking the same defense system as bacteria would allow them to not only cut up sections of DNA but even remove and replace sections.

Wired reported, “Working together, Charpentier’s and Doudna’s teams found that Crispr made two short strands of RNA and that Cas9 latched onto them. The sequence of the RNA strands corresponded to stretches of viral DNA and could home in on those segments like a genetic GPS. And when the Crispr-Cas9 complex arrives at its destination, it does something almost magical: It changes shape, grasping the DNA and slicing it with a precise molecular scalpel.”

It quickly became apparent that this routine, if executed correctly, could become a very powerful tool.

From human health to energy production it could transform genetic engineering. From what they could tell this did not need to be limited to viruses, this “guide RNA” Cas9 “proved to be a programmable machine for DNA cutting”.

In 2012 Dounda’s team published their work and results in Science claiming their technology could be a cheap and useful tool in gene editing. Wired reported, roughly 200 papers had mentioned CRISPR and by 2014 that number tripled.

Dounda and Charpentier were awarded a $3 million Breakthrough Prize and Time magazine recognized both women as two of the most influential people in the world.

Their patent will go on to be represented by UC Berkeley, under the assumption that they own rights to the original discovery of CRISPR.

However, while they were discovering this ‘cut and paste’ method for editing gene sequences another team was filing a patent for the very same process but outside of a test tube.

A Race To The Finish Line

In 2012, molecular biologist Feng Zhang at the Broad Institute of MIT and Harvard, was also working with Crispr-Cas9 but with a focus on its human-therapy applications.

Wired reported, “Doundna’s team had cut DNA floating in a test tube, but to Zhang, if you weren’t working with human cells, you were just screwing around” said Zhang.

Zhang’s work is based on the original patent held by The Broad Institute (MIT & Harvard), Doudna’s competition. Zhang’s work will be affected depending on which way the debate lands. While he currently has exclusive rights to the patent that could change should Dounda and her team receive official credit for the work.

Since the initial discovery all three scientists have co-founded their own companies to conduct further research in what they believe to be the best use of this technology.

Each company is working to discover the breakthrough drug that will finally commercialize CRISPR-Cas9.

When the time comes, untold trillions in predicted revenues will flow into these three biotechs and in turn will have your portfolio overflowing with potential profit.

And when this happens I’ll be right back here to make sure you’re the first to know.

For Technology Profits Daily,

Ray Blanco
Chief Technology Expert, Technology Profits Daily


You won’t hear about THIS tape in the mainstream media – they don’t want you to see it.

Click Here Now to See The Clip and Learn How YOU Can Get YOUR Check Too!

You May Also Be Interested In:

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco